Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$37.39 USD
+0.51 (1.38%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $37.38 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APLS 37.39 +0.51(1.38%)
Will APLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Other News for APLS
Roche failure removes potential downside for Apellis, says Baird
Apellis Pharmaceuticals (APLS) Receives a Buy from Stifel Nicolaus
Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor’s Clinical Failure
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)